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Abstract
The Global Program to Eliminate Lymphatic Filariasis (LF) relies on rapid diagnostic tests
(RDTs) to determine where annual mass drug administration for LF is required and when it
can be stopped. These tests detect a Wuchereria bancrofti glycoprotein in the blood of
infected persons via a carbohydrate moiety recognized by the monoclonal antibodies AD12
and DH6.5. Loiasis cross-reactivity with LF RDTs has recently been recognized as a serious
obstacle to LF elimination in loiasis-endemic areas. To better understand the nature of this
cross-reactivity, we used the DH6.5 antibody to immunoaffinity purify Loa loa antigens from
the sera of individuals with a positive RDT due to loiasis. Immunoblot analysis revealed
many circulating AD12/DH6.5-reactive antigens, and proteomic analysis identified multiple
L. loa proteins in LF RDT-positive loiasis sera. These included both secreted and somatic
proteins, suggesting that they may be released by dying L. loa adult worms and/or microfilar-
iae. Unlike the single high molecular weight W. bancrofti circulating filarial antigen that is reli-
ably present in the blood of persons with bancroftian filariasis, reactive L. loa antigens
appeared to be only transiently present in the blood of a subset of persons with loiasis.
These key differences between the circulating antigens of W. bancrofti and L. loa can be
used to differentiate positive results generated by both species and may lead to improved
diagnostic tests for LF and loiasis.
Author summary
Lymphatic filariasis is a disfiguring parasitic infection tens of millions of people in more
than 70 countries. The global effort to eliminate LF transmission via mass drug adminis-
tration (MDA) relies on rapid diagnostic tests (RDTs) to identify infected individuals and
map afflicted areas. This effort is complicated in loiasis-endemic nations of central Africa
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for two reasons. First, persons with heavy L. loa infections may suffer severe adverse
events, including death, following treatment with MDA medications. Second, it is now
clear that RDT testing for LF can be unreliable in areas with loiasis, since many L. loa-
infected individuals, especially those with heavy infections, test positive by LF RDT in the
absence of infection with W. bancrofti (the causative agent of LF in Africa). We report
here the identity and characteristics of multiple L. loa antigens found in RDT-positive sera
that bind to antibodies used in LF RDTs. Understanding the differences between these
cross-reactive antigens and the circulating filarial antigen of W. bancrofti may lead to
development of improved diagnostic tests for LF and loiasis to facilitate elimination of
filarial infections in Sub-Saharan Africa.
Introduction
Lymphatic filariasis (LF) is a disabling and disfiguring disease caused by mosquito-borne, filar-
ial (threadlike) parasitic worms. The Global Program to Eliminate LF (GPELF) reduced the at-
risk population for LF from 1.2 billion to 789 million (a 46% reduction) between 2000 and
2012 by providing repeated, annual rounds of anti-filarial medications by mass drug adminis-
tration (MDA). However, LF elimination in Africa lags behind other endemic regions with
only a 25% reduction [1]. This is due in part to slow rollout of MDA in regions of central
Africa co-endemic with Loa loa, because drugs used for MDA can cause severe adverse effects
in people with loiasis [2].
The GPELF strategy relies on point of care rapid diagnostic tests (RDTs) to map regions
endemic for LF and to determine when regions have successfully eliminated the disease. Two
RDTs have been used to detect a circulating antigen of Wuchereria bancrofti, the filarial species
that causes LF in Africa. These are the Binax NOW Filariasis immunochromatographic card
test (ICT), and the Alere Filariasis Test Strip (FTS). The FTS is more stable, more sensitive,
and less expensive than the ICT [3], but both are lateral flow assays that work as follows.
Whole blood is applied to a sample pad containing colloidal gold-conjugated polyclonal antifi-
larial antibodies. The sample pad retains blood cells, while capillary action pulls the serum
across the test strip and over a test line containing an immobilized IgM class monoclonal anti-
body called AD12. The AD12 antibody binds a carbohydrate epitope that is abundantly pres-
ent on a high molecular weight (200–250 kDa) W. bancrofti circulating filarial antigen (CFA)
[4, 5]. AD12 traps W. bancrofti CFA bound to the colloidal gold-labeled polyclonal antibodies
to form a pink line that indicates a positive test result.
The molecular structure and saccharide composition of the carbohydrate epitope recog-
nized by the AD12 antibody is unknown. This carbohydrate moiety, which we refer to as the
AD12 epitope, appears to be specific to nematodes and is not phosphorylcholine [5]. A second
IgM monoclonal antibody developed in the Weil laboratory, DH6.5, also recognizes the AD12
epitope [5], and we use these two antibodies interchangeably. Like the AD12 carbohydrate epi-
tope, the exact identity of the high molecular weight W. bancrofti CFA remains unknown. It is
clear, however, that it contains multiple AD12 epitopes per molecule, since capture of the mol-
ecule by DH6.5 in an ELISA format does not prevent AD12 / DH6.5 from binding to the non-
bound surface of the molecule [6]. While other nematodes have antigens that contain the
AD12 epitope [5], the ICT and FTS tests have been considered functionally specific for W.
bancrofti infection, since until recently, such antigens had not been found circulating in the
blood of persons with other infections.
Loa loa antigens cross-reactive with rapid diagnostic tests for lymphatic filariasis
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006963 November 16, 2018 2 / 18
work was supported by National Institute for
Allergy and Infectious Disease (NIAID) grant
K08AI121422 (PJB), and by funds from
Washington University in St. Louis (collection of
Akonolinga/Awae samples) and an NIH Loan
Repayment Programs (NIAID) award. Further
support was provided by the Coalition for
Operational Research on Neglected Tropical
Diseases (COR-NTD, http://www.ntdsupport.org/
cor-ntd, collection of East Region samples,
awarded to SW and PUF) and the Bill and Melinda
Gates Foundation (https://www.gatesfoundation.
org/, grant OPPGH 5342 awarded to PUF and GW).
The funders had no role in study design, data
collection and analysis, decision to publish or
preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
It has now become clear, however, that some persons with loiasis, especially those with high
L. loa microfilaria (Mf) counts, have positive LF RDT results [7–9]. This complicates mapping
and monitoring for LF elimination programs in central Africa. Therefore, the purpose of this
study was to identify filarial antigens in the blood of persons infected with L. loa that could
cause false-positive LF RDT results. This information may lead to the development of
improved diagnostic tests for both infections.
Materials and methods
Ethics statement
This research involved the testing of adult human sera. Sample collection was approved by
the institutional review board of Washington University in St. Louis based on protocols
201512112 for Akonolinga/Awae and 201512016 for the East Region collections in Cameroon.
The studies were also approved by the Cameroon National Ethics Committee and Ministry of
Public Health. Written informed consent was obtained from all participants. The L. loa micro-
filariae harvested from baboons kindly provided by S. Wanji were approved by the Ministry of
Scientific Research and Innovation of Cameroon (Research permit #028/MINRESI/B00/C00/
C10/C12). Animal experiments were conducted within the guidelines stated by the animal
care and use committee at the National Institutes of Health (USA).
Sample collection
We collected plasma and serum samples in two field studies (Fig 1). The first was conducted in
the Akonolinga and Awae health districts (Central Region of Cameroon) in February 2016, for
the specific purpose of obtaining serum samples from persons with loiasis that were positive in
LF RDTs. The second study, conducted in the East Region of Cameroon in December 2016,
was part of an effort to re-map areas of Cameroon for the presence of W. bancrofti and L. loa.
Both study areas are endemic for L. loa and Mansonella perstans, but most likely not for W.
bancrofti (Wanji and co-workers, pers. commun.). Neither area had received community-
based ivermectin treatment or MDA for LF prior to these studies.
The goal of the Akonolinga/Awae study was to obtain serum samples containing cross-
reactive L. loa antigens from at least ten persons with positive ICT tests due to loiasis. We
planned a sample size of 200 participants, based on the assumption that about 10% of persons
with L. loa microfilaremia would have a reactive test [7]. We specifically recruited adults with
known loiasis in prior studies, but also invited adults with unknown infection status living in
the same villages to participate in order to generate a biobank of loiasis positive and negative
samples. Potential participants gathered at a central location in each village (usually the health
center) and were informed of the purpose of the study. Consenting participants underwent
day (10 AM to 2 PM) and night (10 PM to 2 AM) blood collections. Fresh fingerprick capillary
blood was used for ICT testing (100 μL) and for preparation of thick blood smears (70 μL).
Dried blood spots were collected for subsequent PCR testing (90 μL, applied to HemaSpot car-
tridges, Spot On Sciences, Inc., Austin, TX). Venous blood (~10 mL) was collected in K2 ethyl-
enediaminetetraacetic acid (EDTA) vacutainer tubes (BD Biosciences, Franklin Lakes, NJ),
stored overnight at 4˚C, and then separated by centrifugation. Following separation, plasma
was stored at 4˚C for up to 3 days prior to transport to Yaounde´, then stored at -80˚C. Dried
blood spots and aliquots of plasma samples were shipped on dry ice to Washington University
in St. Louis for further analysis. After finding that none of the participants in the first study
were ICT-positive (see Results), we obtained sera from eleven FTS-positive participants of an
initially unrelated study in the East Region of Cameroon. The purpose of the East Region
study was to re-map the prevalence of LF and loiasis in Cameroon, and the primary results of
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that study will be published separately. The re-mapping study was conducted in the Lomie,
Doume and Nguelemendouka health districts. Following a brief interview, consented individ-
uals underwent serological and parasitological testing. Daytime (between 10 AM and 4 PM)
capillary blood was tested for CFA by FTS (70 μL) and for Mf by thick calibrated thick blood
film smears (TBS, 50 μL). Daytime venous blood (4 mL) was collected from FTS-positive indi-
viduals in vacutainer tubes without anticoagulant, and sera were separated using a centrifuge
and stored in cryovials at -20˚C for up to 7 days in the district facilities prior to transport to
Buea, where they were stored at -80˚C. Night TBS were prepared between 10 PM and 2 AM
from participants that tested positive by FTS. Night blood dried onto filter paper was used for
detection of parasite DNA by qPCR, as reported previously [7, 10]. Sera from the re-mapping
study were shipped on dry ice to Washington University in St. Louis for further analysis. Loia-
sis-negative banked sera (collected outside of Africa) from persons with microfilaremic W.
bancrofti infections [11, 12] were used as positive controls for CFA tests.
Detection of Mf in blood samples
Thick blood smears were stained with Giemsa, and the number of L. loa and M. perstans Mf
were counted as previously described [13]. M. perstans were distinguished from L. loa based
on morphology and size. Each slide was read by two experienced microscopists.
Fig 1. Field studies and samples tested. (A) Central Cameroon field study. Because the three FTS positive samples were very weakly positive by FTS and negative by
ICT, we chose not to examine them further. (B) East Region study. Participants who were ICT-positive on initial screening were visited the following week for venous
blood collection. Nine venous blood samples were FTS-positive. Two of these tested negative for filarial antigen by ELISA; the other seven were tested further by ELISA
and/or western blot as indicated. Gray shading indicates the origin of the samples used in the proteomic analysis.
https://doi.org/10.1371/journal.pntd.0006963.g001
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Quantitative PCR
qPCR was performed at Washington University as previously described [7]. Briefly, three
blades of HemaSpot finger prick blood were used for DNA extraction by QIAamp DNA mini
kits (Qiagen, Valencia, CA) Real-time PCR using Taqman Multiplex master mix (Applied Bio-
systems, Foster City, CA) was performed with an ABI Quant 6 instrument under standard
conditions using primer and probe sequences as previously described [10, 14].
W. bancrofti RDTs
The ICT (BinaxNow Filariasis) and Filariasis Test Strip (FTS) (both purchased from Alere,
Scarborough, ME) diagnostic tests for circulating filarial antigen were performed according to
the manufacturer’s instructions and read 10 minutes after applying the sample to the sample
pad [3]. Positive results were recorded with a semi-quantitative scale in which: 0 = no test (T)
line visible (negative), 1 = the T line was visible but weaker than the control (C) line, 2 = the T
line was equal to the C line, and 3 = the T line was stronger than the C line.
In vitro culture of L. loa
L. loa Mf were isolated and purified from venous blood collected from experimentally infected
baboons [15]. Immature adult stage (L5) L. loa were isolated from Rag2-/-/IL2γc-/- BALB/c
mice 90 days after subcutaneous inoculation of 100 L3 stage worms. Pools of parasites (40,000
Mf and 5 L5) were incubated in 400 μl serum-free RPMI medium supplemented with 2mM L-
glutamine, 2 g/L Na2HCO3 with 10% (v/v) penicillin-streptomycin-neomycin mixture in a
37˚C/ 5% CO2 incubator. Culture supernatants (ES) applied directly to FTS after incubation
for 32 hours (Mf) or 24 hours (L5) to detect the presence of reactive antigens.
Filarial antigen ELISA
Detection of circulating filarial antigen by sandwich ELISA was performed as previously
described [6]. This assay uses two IgM monoclonal antibodies, AD12 and DH6.5, both of
which recognize the AD12 carbohydrate epitope. Reagents for ELISA, immunoprecipitation
and immunoblot experiments were purchased from Sigma-Aldrich (St. Louis, MO), unless
otherwise noted.
Competition assay for antibody to the AD12 epitope
Brugia malayi excretory secretory products (Bm-ES) were prepared by incubating adult female
B. malayi worms (obtained from the Filariasis Research Reagent Resource Center, Athens,
GA) in serum free RPMI 1640 media, supplemented with L-glutamine and penicillin/strepto-
mycin (Gibco) in a 37˚C/ 5% CO2 incubator. The spent media was collected every other day
while worms were viable (approximately 2 weeks) and Bm-ES was concentrated by centrifugal
filtration using an Amicon Ultra 3000 MWCO (Millipore) filter. Polyvinyl, U-bottom microti-
ter plates (Thermo Electron Corp., Milford, MA) were coated overnight at 37˚C with 100 μl/
well of Bm-ES product diluted to 1.25 μg/mL in 0.6M carbonate buffer, pH 9.6. After coating,
wells were washed with phosphate buffered saline (PBS) containing 0.05% Tween 20 (PBS-T)
then blocked with 200 μL 5% fetal calf serum in PBS-T. Wells were then incubated with 50 μL
of a 1:5 dilution of test sera or unlabeled DH6.5 antibody (7μg/mL) for one hour at 37˚C,
washed with PBS-T to remove unbound antibody, and incubated with 100 μL peroxidase-con-
jugated AD12 antibody for one hour at 37˚C. Wells were washed three times with PBS-T, and
100 μL O-phenylenediamine dihydrochloride (OPD) substrate added, developed for ten min-
utes, stopped by adding 30 μL of 4M sulfuric acid, and absorbance read at 492 nm.
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Immunoprecipitation
Five mg of antibody DH6.5 was directly conjugated to 1mL packed Affigel 10 beads (Bio-Rad,
Hercules, CA) according to the manufacturer’s protocol. Fifty microliters of conjugated beads
were mixed with 100–750 μl of each human serum sample (depending on the amount of sam-
ple available), then incubated at 4˚C with rocking overnight. The beads were then washed four
times with cold PBS, re-suspended in 1X NuPAGE LDS sample buffer (Invitrogen), and heated
to 95˚C for five minutes to release bound antigens. For L. loa ES products, one mL of in vitro
culture supernatant was mixed with 50 μL DH6.5-conjugated beads and rocked at 4˚C over-
night. The beads were washed four times with cold PBS, four times with a high salt, detergent
buffer (MIB-T buffer: 5mM HEPES, 1M NaCl, 1mM EDTA, 1mM EGTA, 10mM NaF, 2.4mM
NaVO4, 0.5% Triton X-100 + protease inhibitor cocktail), then twice in cold PBS to remove
the detergent. Antigens were released by heating in 1X NuPAGE LDS sample buffer as written
above.
Polyacrylamide gel electrophoresis and western blot analysis
Proteins were resolved by SDS-PAGE using a 4–12% bis-tris NuPAGE gel (Invitrogen) and
transferred to nitrocellulose membranes (Cell Signaling Technology, Danvers, MA). Mem-
branes were incubated 1 hour at room temperature with PBS-T containing 5% nonfat, dried
milk to block nonspecific binding and then incubated with a 1:1000 solution of peroxidase-
conjugated AD12 antibody in blocking buffer for one hour at room temperature. Blots were
washed three times in PBS-T, incubated with Clarity Western ECL substrate (Bio-Rad, Hercu-
les, CA), and bound antibody detected by chemiluminescence using a Bio-Rad ChemiDoc
instrument and Image Lab 5.2.1 software. The L. loa soluble antigen (Loa Ag) used as a positive
control in the immunoblots was prepared by grinding adult L. loa worms in extraction buffer
(10mM Tris pH 8.3, 2% sodium deoxycholate, 1mM PMSF, 1mM EDTA, 1mM EGTA, 25ug/
mL TLCK protease inhibitor, 15ug/mL TPCK protease inhibitor). The adult worms were a gift
from Dr. Vida Dennis, Tulane University.
Liquid chromatography-tandem mass spectrometry (LC-MS/MS)
Immunoprecipitation samples were prepared for LC-MS/MS using the filter-aided sample
preparation method [16]. Briefly, samples were reduced with DTT and buffer-exchanged into
8M urea/Tris, alkylated with 40mM iodoacetamide, then buffer-exchanged in several steps to
0.05M NH4HCO3 using a Microcon 30K filter concentrator (Millipore, Billerica, MA). Sam-
ples were treated with PNGase F for 1–3 hours to remove N-linked carbohydrates. The sam-
ples were then resuspended in urea/tris, reduced with TCEP, incubated with iodoacetamide to
block reactive thiols, and buffer-exchanged back into 0.05M NH4HCO3. Trypsin, chymotryp-
sin, or both were added and samples were incubated overnight at 37˚C, after which the
digested peptides were centrifuged through the 30K filter and desalted using a Glygen C4 tip
(Glygen, Columbia, MD). LC-ESI/MS/MS analysis was performed using a Q-Exactive Plus
Hybrid Quadrupole-Orbitrap Plus mass spectrometer (ThermoFisher Scientific) coupled to an
EASY-nanoLC 1000 system (ThermoFisher Scientific). The samples were loaded (2.5 μL) onto
a 75 μm × 50 cm Acclaim PepMap 100 RP column (ThermoFisher Scientific). The peptides
were eluted at a flow rate of 300 nL/min with an acetonitrile gradient in aqueous formic acid
(0.1%) as mobile phase A. Peptide elution occurred in the following sequence: 0–4% buffer B
(Acetonitrile containing 0.1% formic acid) for 1 min, 4–12% over 63 minutes, 12–22% B over
56 minutes, 22–30% B over 20 minutes, 30–70% B over 6 minutes, followed by increase in B to
95% B over 1 min and an isocratic wash at 95% B for 12 min. Full-scan mass spectra were
acquired by the Orbitrap mass analyzer in the mass-to-charge ratio (m/z) of 375 to 1500 and
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with a mass resolving power set to 70,000. Twelve data-dependent high-energy collisional dis-
sociations (HCD) were performed with a mass resolving power set to 35,000, a fixed first m/z
100, an isolation width of 1.2 m/z, and the normalized collision energy (NCE) setting of 27.
The maximum injection time was 120 ms for parent-ion analysis and 120 ms for product-ion
analysis. Target ions already selected for MS/MS were dynamically excluded for 30 sec. An
automatic gain control (AGC) target value of 3 x 106 ions was used for full MS scans and 5 x
105 ions for MS/MS scans. Peptide ions with charge states of one or greater than seven were
excluded from MS/MS acquisition. The resulting MS spectra were converted to Mascot generic
format (MGF) using Proteome Discoverer v2.1.0.81. MGF files were submitted for peptide
identification against target databases available for L. loa (Bioprojects PRJNA246086 [17] and
PRJNA60051 [18] downloaded from WormBase ParaSite (parasite.wormbase.org) on Feb 27,
2017), contaminant databases from ENSEMBL for Human (Homo_sapiens.GRCh37.72
ENHU) and Mouse (Mus_musculus.GRCm38.72 ENMOU), and the cRAP database version
(2012.01.01) for common contaminating peptides (http://www.thegpm.org/crap/). The search
engine used was PEAKS Studio 8.0 build 20160908. The following parameters were used dur-
ing database search: Oxidation of methionine was allowed as variable modification; carbami-
domethylation of cysteine as a fixed modification; maximum of 3 missed cleavages; trypsin
and chymotrypsin as the proteolytic enzymes depending on the sample; MS1 error tolerance
of 20.0 ppm and MS2 error tolerance of 0.02Da. Qualifying peptides had a less than 1% false
discovery rate and were absent from the combined control databases with human, mouse and
common contaminating peptides.
Bioinformatic analysis
Blast2Go software was used to assign Gene Ontology (GO) terms to the combined immuno-
precipitation (IP) dataset and to the whole genome of Loa (PRJNA246086) to build a reference
database [19]. NetOGlyc 4.0 was used to predict O-glycosylation sites in the hits from the mass
spec analysis. These results were compared with the O-glycosylation prediction of 500 ran-
domly selected proteins from the genome to determine enrichment of O-glycoproteins [20].
The same approach used to predict N-glycosylation sites with NetNGlyc 1.0 [21]. SignalP 4.1
software was used to predict classical N-terminus secretion signals and SecretomeP 2.0 was
used to predict non-classical secretion signals [22, 23]. Reciprocal BLAST searches with the B.
malayi genome (BioProject PRJNA10729, parasite.wormbase.org) were used to identify B.
malayi homologs of the L. loa antigens identified in the proteomics screen. The resulting data-
set was used for a meta-analysis of B. malayi proteomics studies as a proxy to characterize the
L. loa proteins.
Results
Loss of ICT cross-reactivity in residents of Akonolinga/Awae
Prior filariasis surveys in the Akonolinga and Awae health districts in Central Cameroon area
had shown 1–5% ICT positivity with a W. bancrofti microfilaremia prevalence of 0.23%. This
result suggested that most, if not all, of the ICT positives were due to L. loa cross reactivity
[24]. In February 2016, we collected daytime and nighttime blood samples from 183 persons.
This included 89 persons who had tested positive for loiasis in prior studies, and 18 who were
previously ICT positive (tested in either 2013 or 2015; S1 Table). One hundred eleven partici-
pants (59%) had L. loa microfilaremia in blood collected during the day, and 71 (41%) of these
also had nocturnal L. loa microfilaremia. No participant had W. bancrofti microfilaremia by
microscopy and only one sample, which was FTS negative, tested positive for W. bancrofti
DNA by qPCR. Surprisingly, none of the participants were ICT positive, including the 18 who
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had been ICT positive in prior studies, even though L. loa Mf counts in these participants had
not decreased (Table 1). We also tested plasma from each participant by FTS; and only three
samples were weakly positive (1+ test line).
Loss of reactivity is not due to masking antibody
It has been observed that the absence of circulating filarial antigen in some W. bancrofti-
infected individuals is related to the host humoral response to the AD12 epitope [6]. To inves-
tigate whether the lack of W. bancrofti RDT cross-reactivity in the previously ICT-positive par-
ticipants was due to development of antibodies against the AD12 epitope in these persons, we
tested a subset of samples for anti-AD12 epitope antibody by competition ELISA. None of the
samples reduced binding of the AD12 antibody to AD12 epitopes by more than 20%, regard-
less of the current or prior ICT/FTS status of the individual (Fig 2). This suggests that the lack
of RDT-positivity in the previously positive samples is not due to the presence of AD12 epi-
tope-masking antibodies.
East Region samples
Given the lack of cross-reactive antigenemia in the Akonolinga/Awae participants, we also
tested banked sera from eleven ICT-positive participants in an integrated LF re-mapping
study conducted in the East Region of Cameroon in 2016. These participants all had L. loa
microfilaremia (Table 2) but no W. bancrofti Mf by nocturnal thick blood smear and no
detectable W. bancrofti DNA by qPCR. All 11 participants also had M. perstans microfilaremia.
Nine of the eleven sera were FTS positive, and four had detectable AD12 epitope-containing
antigen by CFA ELISA (Table 2 and Fig 1).
Western blot analysis of cross-reactive sera
We tested FTS-positive samples by western blot to visualize antigens reactive with AD12. Sam-
ple P811355, which had the highest antigen level, was analyzed separately; six other samples
with weaker antigen signals by FTS were pooled (see Table 2) for analysis. We captured AD12
epitope-containing antigens by incubating these sera with agarose beads conjugated to DH6.5
monoclonal antibody, which recognizes the same carbohydrate epitope as AD12, and then
detected the bound proteins by western blot using horseradish peroxidase-conjugated AD12
antibody. Both sample 811355 and the pooled serum sample contained many reactive proteins
including a major band at ~80 kDa. This pattern is very different from that seen with sera
from W. bancrofti-infected persons (Fig 3). Serum samples from LF RDT-negative loiasis
serum, including five individuals from the Akonolinga/Awae field study who were previously
W. bancrofti RDT positive but negative at the time of our study, were negative for AD12 con-
taining antigens by western blot.
Proteomic analysis of L. loa antigens immunoprecipitated from human
serum with monoclonal antibody DH6.5
We next analyzed immunoaffinity-purified antigens from sample 811355 and the pooled sera
by protease digestion and LC-MS/MS, matching MS spectra to both available L. loa genomes
[17, 18]. After reconciling duplicated annotations between the two genomes, 220 L. loa pro-
teins with two or more unique peptides were detected in the 811355 sample; ten were detected
in the pooled sera. Seven proteins were detected in both samples. Table 3 lists the most abun-
dant proteins identified; a list of all identified proteins is provided in S2 Table.
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Bioinformatic analysis
To further characterize the loiasis antigens captured by DH6.5 immuno-purification, we per-
formed a gene ontology (GO) enrichment analysis using Blast2Go software [19, 25] with the
published L. loa proteome as a comparator [17]. At least one GO term could be assigned for
206 of the 220 (94%) loiasis proteins identified. Table 4 shows the top ten GO terms enriched
in each category. Compared to the whole L. loa proteome, our identified proteins were
enriched for cytoplasmic, organelle, and cytoskeletal proteins. The over-represented molecular
functions included structural and protein binding activity, as well as nucleoside enzymatic
activity and purine nucleoside binding. The biological processes enriched in the IP were
largely concerned with reproduction and early development.
Analysis with secretion signal prediction software SignalP, which searches for classical N-
terminus secretion signals, and SecretomeP, which searches for non-classical secretion signals,
predicted that only 69 of 220 (31%) of the loiasis proteins are likely to be secreted [22, 23]. In
comparison, 246 of 500 (49%, 95% CI: 45%– 54%) randomly selected proteins from the L. loa
genome are predicted to be secreted by these algorithms. Because SecretomeP and SignalP
were designed to predict mammalian, not filarial, protein secretion, we also compared the pro-
teins identified in our screen to the well-characterized B. malayi secretome [26–28]. One
Table 1. Central Cameroon field study L. loa and W. bancrofti test results by prior ICT status.
Prior ICT � ICT+ FTS+ L. loa PCR+ Wb PCR+ Median L. loa Mf/mL (IQR)
Prior results Current results








No prior (N = 135) 0 2 38 (28%) 1 N/A 40
(0–3,880)
�Prior ICT tests were in either 2013 (N = 24) or 2015 (N = 24)
https://doi.org/10.1371/journal.pntd.0006963.t001
Fig 2. Loiasis patient sera lack antibodies specific to the AD12 carbohydrate epitope. Serum samples were tested
for the ability to block AD12 binding to B. malayi antigens that contain the AD12 epitope. The horizontal line denotes
the mean value for each group.
https://doi.org/10.1371/journal.pntd.0006963.g002
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hundred five of the 220 L. loa proteins we identified have clear B. malayi homologs. Eighteen
(17%) of these were present in the B. malayi secretome, twelve of which are reportedly secreted
by Mf, but not by adult worms. Nearly all (92 of 105, 88%) of the B. malayi homologues show
evidence of expression in the B. malayi proteome, and the 71 of 92 (77%), are expressed in all
stages examined [29]. Taken together, these analyses suggest that most of proteins detected by
our screen in loiasis sera are not secreted, and that their source may be either Mf or adult
worms (or both).
Since our purification strategy involved capturing with a monoclonal antibody specific for
the AD12 carbohydrate epitope, we examined the predicted glycosylation status of the L. loa
proteins identified in human serum samples. Eighty-three percent were predicted by NetO-
Glyc 4.0 [20] to have O-linked glycosylation sites, compared to 77% (95% CI: 74%– 82%) of a
random set of 500 L. loa proteins. NetNGlyc 1.0 software [21] predicted that 47% of the L. loa
proteins we identified may have N-linked glycosylation, compared to 18% (95% CI: 14%–21%)
of the randomly selected L. loa proteins. Thus, the majority of proteins identified in our screen
were, as expected, predicted to be glycoproteins. The absence of predicted glycosylation sites
on a minority (20/220, 9%) of the identified proteins suggests that a fraction of the proteins we
identified are not decorated with the AD12 glycan epitope.
Analysis of excretory-secretory products from cultured L. loa worms
Both L. loa Mf and explanted L5 (adult) worms cultured ex vivo secrete antigens that cross-
react with W. bancrofti RDTs [15]. To identify these secreted antigens and to determine if they
were among those present in patient sera, we examined the excretory/secretory (ES) products
from adult female worms and from Mf cultured in vitro. Using DH6.5-conjugated beads to
capture AD12 epitope-containing antigens, we detected several AD12-reactive antigens in the
culture supernatants of adult female worms by western blot, but none were detected in Mf
supernatants (Fig 4). LC MS/MS analysis identified four L. loa proteins in the adult (L5) super-
natants that met the pre-specified requirement of having at least two unique peptides detected.
Only one of these proteins, the L. loa ortholog of filarial antigen Av33, was also detected in
loiasis sera (Table 5).
Table 2. Summary of Mf burden and antigenemia in ICT/FTS cross-reactive L. loa infected individuals from East
Region Cameroon mapping study.
Sample ID# L. loa (Mf/mL) FTS score CFA (ng/mL) M. perstans (Mf/mL)
P811473 13600 0 0 1200
P811092 41650 0 0 900
P811331� 9750 1 5.8 1150
P811493� 7700 1 ND 1950
P811461� 21450 1 81.4 8650
P811408� 44350 1 ND 6650
P811377� 74350 1 86.3 1800
P811161 50100 1 0 550
P811264 16800 2 0 950
P811134� 59500 2 ND 1000
P811355 82950 2 >400 900
�Serum pooled in further analyses
ND = insufficient sample volume to conduct CFA ELISA
https://doi.org/10.1371/journal.pntd.0006963.t002
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Discussion
Reactivity of circulating L. loa antigens with W. bancrofti RDTs is an impediment to successful
LF elimination in loiasis-endemic areas in Central Africa, because a CFA prevalence of 1% or
higher is considered to be evidence that the area is endemic for LF and should receive MDA
[30]. In this study we sought to identify L. loa antigens that are responsible for false-positive
results in LF RDTs. This work led to several unexpected observations. First, RDT cross-reactiv-
ity was absent in many persons previously ICT-positive despite persistence of high L. loa
microfilarial loads. The mechanism of loss of cross-reactivity is unclear, but it does not appear
to be due to masking of the AD12 epitope by antibodies. It also seems unlikely that changes in
the performance characteristics of the ICT were responsible; we contacted Alere and were
assured no changes in the manufacturing process or quality control testing of the ICT were
made between 2013 and 2016. Second, unlike bancroftian filariasis, where RDT positivity is
associated with a single circulating filarial glycoprotein, cross-reactive loiasis sera contain mul-
tiple AD12 epitope-containing L. loa antigens. Most of these antigens are not predicted to be
secreted and are related to intracellular processes and structures. In addition, most are not spe-
cific to any particular stage of the filarial lifecycle. Only one of the L. loa antigens identified in
Fig 3. Loiasis sera positive by LF RDT contain multiple AD12 epitope-containing antigens. (A) AD12 western blot
showing reactive bands in pooled sera from 13 individuals with W. bancrofti infection (Wb CFA+) or 12 uninfected
individuals (CFA-). (B) Antigens from sample P811355 (355), and pooled cross-reactive sera. Soluble L. loa antigen
(Loa Ag, 0.5 μg) served as a positive control. Because the antigen level was much higher in sample P811355 than in the
pooled sample, different chemiluminescent exposure times were used for the same blot (45 seconds for soluble L. loa
antigen and P811355; 15 minutes for the pooled serum sample).
https://doi.org/10.1371/journal.pntd.0006963.g003
Loa loa antigens cross-reactive with rapid diagnostic tests for lymphatic filariasis
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006963 November 16, 2018 11 / 18
cross-reactive sera was also detected in excretory/secretory products of ex vivo cultured L. loa
adults.
These results suggest that the release of cross-reactive L. loa antigens occurs by a process or
processes quite different from that of the W. bancrofti CFA [5]. We believe that the most likely
mechanism for loiasis cross-reactivity with W. bancrofti RDTs is death of L. loa Mf and/or
adult worms associated with release of multiple AD12 glycoproteins into circulation and that
imbalance between release and clearance of these antigens accounts for their detection in the
circulation of some loiasis patients. It is known that not all loiasis patients with active infection
(as indicated by the presence of eye worms) have circulating L. loa Mf, and this is believed to
be due to immune clearance of Mf. Perhaps immune-mediated clearance of Mf results in inter-
mittent release of AD12 epitope-containing antigens. Another explanation would be that the
antigens are released by the intermittent death of adult worms. Either of these mechanisms
Table 3. Proteins identified in cross-reactive L. loa sera.
Unique peptides (total
spectral counts)
Description ID1 LOAG ID2 C. elegans ortholog3
811355 Pooled
76 (93) 2 (2) Myosin heavy chain 4 EN70_1344 - unc-54
29 (63) 21 (30) Hypothetical zinc metalloprotease EN70_10459 - nas-14
21 (30) 2 (2) Sugar transporter EN70_10241 LOAG_09566 fgt-1
18 (21) 3 (3) Tropomyosin - LOAG_17659 lev-11
2 (2) 1 (12) Hypothetical zinc metalloprotease EN70_104634 - nas-14
2 (19) 1 (12) Hypothetical zinc metalloprotease EN70_10462 - nas-14
2 (17) 5 (5) Myosin heavy chain - LOAG_18869 unc-54
41 (53) - Paramyosin EN70_1595 LOAG_05509 unc-15
31 (34) - Mesocentin - LOAG_01560 dig-1
30 (40) - Chaperonin GroEL EN70_9299 LOAG_17523 hsp-60
30 (34) - ATP synthase subunit beta EN70_3459 - atp-2
24 (24) - Spectrin protein 1 EN70_4597 LOAG_16411 add-1
22 (34) - Galectin-2 EN70_3647 LOAG_01794 lec-2
21 (28) - Heat shock protein 90 EN70_561 - daf-21
21 (26) - ADP/ATP carrier protein EN70_6911 LOAG_07239 ant-1.1
20 (20) - Spectrin beta chain EN70_174 LOAG_04011 unc-70
19 (21) - Myosin light chain EN70_10990 LOAG_04932 mlc-3
18 (26) - Myosin regulatory light chain 1 EN70_948 LOAG_03316 mlc-1
18 (20) - Calcium-transporting ATPase EN70_10268 - sca-1
17 (21) - Phosphate carrier protein EN70_6829 LOAG_00237 F01G4.6
15 (17) - Sodium/potassium-transporting ATPase subunit alpha EN70_7308 LOAG_07650 catp-4
14 (17) - ATP synthase subunit alpha EN70_7528 LOAG_16780 H28O16.1
12 (13) - Hypothetical protein, adhesion domains EN70_5928 - dig-1
12 (12) - Chaperone DnaK EN70_547 LOAG_16336 hsp-6
11 (14) - Elongation factor 1-alpha EN70_10934 LOAG_08753 eef-1A.1
11 (13) - Disorganized muscle protein 1 EN70_901 LOAG_02014 dim-1
11 (13) - Enolase EN70_8669 - enol-1
1Bioproject PRNJA246086 (Talon et al 2014)
2Bioproject PRNJA60051 (Desjardin et al 2013)
3parasite.wormbase.org
4Nine peptides shared between EN70_10462 and EN70_10463
https://doi.org/10.1371/journal.pntd.0006963.t003
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would be consistent with the observation that although there is a correlation between microfi-
larial load and RDT-positivity, not all persons with cross-reactive RDTs due to loiasis have
detectable microfilaremia [7].
It is important to recognize that while the ICT and FTS rapid diagnostic tests detect a spe-
cific high molecular weight W. bancrofti glycoprotein in serum samples from persons infected
with W. bancrofti, they do so by recognizing a carbohydrate epitope (the AD12 epitope) that is
not unique to W. bancrofti. This epitope is present on multiple proteins in lysates of Dirofilaria
and Brugia [5, 6]. While AD12 epitope-containing proteins are present in somatic antigen
preparations and ES products of L. loa Mf and L3 larval stages [15], the developmental stage
from which the cross-reactive antigens in serum originate remains unclear. Our set of 220 L.
loa proteins resembles microfilarial or immature uterine expression signatures based on
Table 4. GO enrichment analysis of mass spectrometry hits.
GO ID GO Name Fold Change p-value1
Cellular Compartment
GO:0005737 cytoplasm 2.0 2.3E-17
GO:0044422 organelle part 2.2 8.1E-16
GO:0044446 intracellular organelle part 2.2 2.3E-14
GO:0044444 cytoplasmic part 2.1 6.9E-14
GO:0099512 supramolecular fiber 4.4 1.0E-11
GO:0099081 supramolecular polymer 4.4 1.2E-11
GO:0043228 non-membrane-bounded organelle 2.4 1.2E-11
GO:0043232 intracellular non-membrane-bounded organelle 2.4 1.2E-11
GO:0099080 supramolecular complex 4.3 1.4E-11
GO:0030016 Myofibril 7.4 6.3E-11
Molecular Function
GO:0005198 structural molecule activity 3.9 1.8E-11
GO:0005515 protein binding 2.1 2.5E-08
GO:0017111 nucleoside-triphosphatase activity 2.8 2.9E-07
GO:0016462 pyrophosphatase activity 2.8 4.4E-07
GO:0016818 hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides 2.7 4.9E-07
GO:0003735 structural constituent of ribosome 4.0 5.1E-07
GO:0016817 hydrolase activity, acting on acid anhydrides 2.7 5.4E-07
GO:0035639 purine ribonucleoside triphosphate binding 1.9 2.5E-06
GO:0001883 purine nucleoside binding 1.9 2.6E-06
GO:0032550 purine ribonucleoside binding 1.9 2.6E-06
Biological Processes
GO:0009792 embryo development ending in birth or egg hatching 3.5 1.4E-23
GO:0002119 nematode larval development 3.3 1.1E-21
GO:0002164 larval development 3.3 1.2E-21
GO:0009790 embryo development 3.2 1.9E-21
GO:0009791 post-embryonic development 3.3 3.1E-21
GO:0000003 reproduction 2.7 6.2E-20
GO:0048608 reproductive structure development 4.7 5.1E-19
GO:0061458 reproductive system development 4.7 5.1E-19
GO:0045137 development of primary sexual characteristics 4.6 2.5E-17
GO:0008406 gonad development 4.6 2.5E-17
1based on binomial distribution
https://doi.org/10.1371/journal.pntd.0006963.t004
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number of matches and total spectral counts from a stage specific study of B. malayi [29] and
corresponds well with a L. loa Mf transcription analysis [18]. It seems likely that at least some
of the proteins we detected are of microfilarial origin, which contrasts with Bancroftian filaria-
sis in which the dominant circulating W. bancrofti antigen is produced primarily by adult
worms [5, 31].
Several prior studies have reported circulating L. loa antigens in the blood [32–34] and
urine [35] of persons with loiasis. Our study differed in that we sought to specifically capture
the antigens responsible for W. bancrofti RDT cross-reactivity. It is not surprising, therefore,
that our approach identified different circulating L. loa antigens compared to prior studies.
For example, out of the 18 L. loa proteins identified by Drame et al. in urine from one L. loa
microfilaremic individual, only two, peptidase M16 inactive domain-containing protein
(LOAG_04876) and pyruvate kinase (LOAG_17249), were also found in our analysis [35].
Our study had some significant limitations. First, the difficulty of obtaining cross-reactive
sera and the need to pool the samples that were not strongly positive has resulted in characteri-
zation of only two samples. Whether these findings are representative of all persons with W.
bancrofti RDT cross-reactivity due to loiasis will require further study. Second, since all the
Fig 4. L. loa secretes glycoproteins reactive with monoclonal antibody AD12. Western blot of AD12 glycoproteins
immunoaffinity purified from 1mL of culture supernatant (ES products) from L. loa adult worms (L5) or microfilaria
(Mf). Soluble L. loa antigen (Loa Ag, 0.5 μg) served as a positive control.
https://doi.org/10.1371/journal.pntd.0006963.g004
Table 5. Proteins identified in L5 stage L. loa excretory/secretory products.
Unique peptides (spectra) Description ID1 LOAG ID2 #peptides in loiasis serum3
5 (5) Filarial antigen Av33-like EN70_3801 LOAG_02368 5
2 (2) U6 snRNA-associated Sm-like protein EN70_10442 LOAG_05763 -
2 (2) RAN GTP-binding nuclear protein EN70_6080 - -
2 (2) 14-3-3 zeta EN70_4422 LOAG_05701 -
1Bioproject PRNJA246086 (Talon et al 2014)
2Bioproject PRNJA60051 (Desjardin et al 2013)
3S2 Table
https://doi.org/10.1371/journal.pntd.0006963.t005
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sera we analyzed were from persons co-infected with M. perstans, it is impossible to rule out
detection of some Mansonella proteins in our analyses. It seems unlikely, however, that cross-
reactive Mansonella proteins were prominent, since M. perstans Mf counts were 2.5 to 92
times lower than L. loa Mf counts in the samples we analyzed (see Table 2). Furthermore, prior
studies found no correlation between M. perstans microfilariemia and ICT or FTS positivity
among patients with loiasis [7–9]. It would be interesting to see how many of the proteins
identified in our MS analysis might also be part of the M. perstans proteome; unfortunately,
there is no M. perstans genome available to address this issue at this time.
Second, we cannot be certain which of the antigens we identified actually contribute to
RDT cross-reactivity. The immunoprecipitation conditions we used to capture cross-reactive
antigen (4˚C rocking overnight) differ from the RDTs (room temperature, 10 minutes). We
chose overnight incubation in order to capture as many cross-reactive antigens as possible for
downstream analysis. It is possible that shorter incubation times would capture fewer antigens.
Additionally, because these antigens are glycoproteins, it is impossible to correlate the appar-
ent MW, based on gel electrophoresis, with the proteins identified by shotgun mass spectrom-
etry. Our data therefore identify L. loa antigens present in cross-reactive sera, but do not
establish which antigens are necessary and/or sufficient to cause a cross-reactive RDT. The
presence of a predominant ~80 kDa band in both the #811355 sera and the pooled sera sug-
gests it may be a major contributor. Future studies with larger sample numbers will be neces-
sary to address these questions.
One perplexing aspect of W. bancrofti RDT positivity in loiasis is that only a small percent-
age of samples from persons with loiasis cross-react. Our Akonolinga and Awae field study
adds another piece to this puzzle, since it demonstrates that loiasis cross-reactivity may vary
over time despite persistence of microfilaremia. As mentioned above, we feel the most plausi-
ble explanation for this is an imbalance between the intermittent release of L. loa antigens and
the capacity of the host to clear these antigens. The number and varied intracellular locations
and diverse functions of the antigens detected in cross-reactive sera suggest that the antigens
are coming from dead or dying parasites and not being excreted or secreted from living
worms.
In conclusion, this study has provided new information on cross-reactivity of CFA tests for
LF in persons with loiasis. Prospective studies examining the duration of RDT cross-reactivity
in persons with loiasis (and the factors associated with its development and resolution) may
help to clear up unresolved issues. Our results also demonstrate a method for distinguishing
between lymphatic filariasis and loiasis based on patterns of AD12-reactive antigens in human
sera revealed by western blot. Additional research will be required to develop improved tests
for the specific diagnosis of both of these infections.
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